Market capitalization | $8.97m |
Enterprise Value | $8.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.52 |
P/S ratio (TTM) P/S ratio | 0.51 |
P/B ratio (TTM) P/B ratio | 0.95 |
Revenue growth (TTM) Revenue growth | -0.71% |
Revenue (TTM) Revenue | $17.42m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
2 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
2 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
Jan '25 |
+/-
%
|
||
Revenue | 17 17 |
1%
1%
|
|
Gross Profit | 7 7 |
9%
9%
|
|
EBITDA | -6.29 -6.29 |
19%
19%
|
EBIT (Operating Income) EBIT | -10 -10 |
15%
15%
|
Net Profit | -33 -33 |
215%
215%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Jennifer Bath |
Employees | 101 |
Founded | 1983 |
Website | www.ipatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.